Bharat Biotech, ICMR announce interim results from Phase 3 trials of COVAXIN EP News Bureau Apr 21, 2021 It demonstrates overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19 disease
Moderna begins Phase 3 trials of its COVID-19 vaccine candidate EP News Bureau Jul 27, 2020 The randomised, placebo-controlled trial is expected to include approximately 30,000 participants in the US
